Theriva Biologics, Inc. — filing identification
Filing mismatch: The supplied filing is Synthetic Biologics, Inc.’s Form 10-K for the fiscal year ended December 31, 2012, filed April 16, 2013. It is not a quarterly report for “2012 Q4,” and the filing does not identify Theriva Biologics as the registrant. The company later used a different name, but that history is not established in the supplied text.
Business context and reporting period
Synthetic Biologics was a development-stage biotechnology company focused on biologics and drug candidates, prioritizing infectious diseases while also developing multiple sclerosis treatments and partnering its fibromyalgia program. Its principal programs were SYN-004, an oral beta-lactamase enzyme intended to prevent C. difficile infection; preclinical pertussis antibody SYN-005; an Acinetobacter antibody program at discovery stage; Trimesta for MS; and Effirma, partnered with Meda AB for fibromyalgia.
During 2012, the company acquired the C. difficile program, expanded its Intrexon collaboration, licensed pertussis antibody research from the University of Texas at Austin, raised equity, and sold its clinical laboratory business. It discontinued further development of AEN-100 for ALS and did not intend to continue its PAH program, while discussing a possible replacement program with Intrexon.
Financial results and position
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Continuing operations revenue | No revenue reported | No revenue reported |
| General and administrative expense | $5.012 million | $2.588 million |
| Research and development expense | $12.287 million | $3.340 million |
| Loss from continuing operations | $(17.284) million | $(7.626) million |
| Net loss | $(17.068) million | $(8.149) million |
| Net loss per share | $(0.49) | $(0.29) |
| Net cash used in operating activities | $(8.916) million | $(2.875) million |
| Cash at year-end | $9.954 million | $6.678 million |
Laboratory revenue, reported within discontinued operations, was $115,000 in 2012 versus $1.169 million in 2011. Discontinued operations recorded 2012 income of $216,000, including a $677,000 gain on the laboratory sale, compared with a $523,000 loss in 2011. R&D expense growth primarily reflected non-cash charges of $7.8 million for Intrexon collaboration shares and $1.2 million for shares issued in the C. difficile asset acquisition. G&A growth included higher staffing, investor relations and legal costs.
At December 31, 2012, total assets were $13.423 million, including $12.463 million of current assets; total liabilities were $395,000, all current; and stockholders’ equity was $13.028 million. Working capital was approximately $12.068 million. The balance sheet reported no debt. Cash flow from financing was $12.202 million, including $10.120 million net proceeds from common-stock issuance and $2.082 million from option and warrant exercises. The October 2012 placement generated $10.8 million gross and approximately $10.1 million net proceeds. Cash was approximately $8.7 million as of March 27, 2013.
No operating margin or meaningful commercial-product margin is reported because the company had no continuing-operation revenue. The filing reports an accumulated deficit of $68.941 million and states it had incurred negative operating cash flow in nearly all periods since inception.
Changes, outlook, risks and unusual items
- Material year-over-year change: Net loss more than doubled, while operating cash use increased substantially. Expenses rose as the company expanded development programs and recorded non-cash equity compensation and collaboration charges.
- Liquidity outlook: Management said existing cash was expected to fund planned operating needs for at least the next 12 months, but emphasized that estimates could prove wrong. The company had no committed financing and might need additional equity, debt, partnership or licensing proceeds; future financing could be unavailable or dilutive.
- Pipeline outlook: Trimesta’s fully enrolled Phase II relapsing-remitting MS trial was expected to deliver top-line results in the first half of 2014 and was supported by grants exceeding $8 million. Enrollment continued in a separate Phase II cognitive-dysfunction trial; the company had pledged approximately $500,000 over three years. SYN-004 was in preclinical development; the acquired first-generation P1A had Phase I and Phase II data. SYN-005 was preclinical, and Acinetobacter antibody discovery was ongoing. Meda reported FDA permission to conduct a Phase II fibromyalgia proof-of-concept study; development costs were Meda’s responsibility.
- Contractual exposure: The company paid Intrexon a $2.5 million R&D prepayment, recorded as a current asset. Intrexon agreements also include future milestone payments of $2 million at an IND event and $3 million at approval or first commercial sale, payable in cash or shares, plus royalties and possible $2 million fees for each selected target beyond three. Prev could regain the acquired C. difficile assets if specified development deadlines are missed, subject to contractual extensions.
- Principal risks: Continued losses, lack of product revenue, uncertain access to capital, clinical and regulatory failure, dependence on Intrexon and external researchers, manufacturing constraints, competition, and limited patent protection. Management noted that Trimesta and Effirma lack composition-of-matter patents. The company also cited potential dilution, thin trading and NYSE MKT listing requirements.
- Unusual reporting and governance matters: Berman & Company was dismissed and BDO USA appointed after the company was informed that a partner at the prior auditor was not authorized under PCAOB partner-rotation rules to issue the 2011 audit opinion or conduct certain interim reviews. The 2012 financial statements received an unqualified audit opinion. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-controls attestation.
Important facts for investors to verify
- Confirm the registrant and period: the source is Synthetic Biologics’ annual 2012 Form 10-K, not a Theriva Biologics filing or a standalone Q4 report.
- Review the audited statements and cash-flow assumptions, including the stated 12-month cash runway and subsequent cash balance.
- Check subsequent clinical-trial, regulatory and funding developments against the filing’s 2014 Trimesta milestone expectations and early-stage status of infectious-disease programs.
- Assess dilution and related-party exposure from Intrexon’s equity, milestone, royalty and financing arrangements, as well as the concentration of beneficial ownership.
- Verify the status and collectability of the $700,000 two-year note receivable from the sold laboratory business, due March 1, 2014, and review the auditor partner-rotation issue and subsequent remediation.